TY - JOUR
TI - Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease
AU - Sinakos, E.
AU - Kountouras, D.
AU - Koskinas, J.
AU - Zachou, K.
AU - Karatapanis, S.
AU - Triantos, C.
AU - Vassiliadis, T.
AU - Goulis, I.
AU - Kourakli, A.
AU - Vlachaki, E.
AU - Toli, B.
AU - Tampaki, M.
AU - Arvaniti, P.
AU - Tsiaoussis, G.
AU - Bellou, A.
AU - Kattamis, A.
AU - Maragkos, K.
AU - Petropoulou, F.
AU - Dalekos, G.N.
AU - Akriviadis, E.
AU - Papatheodoridis, G.V.
JO - British Journal of Haematology
PY - 2017
VL - 178
TODO - 1
SP - 130-136
PB - Wiley-Blackwell Publishing Ltd
SN - 0007-1048, 1365-2141
TODO - 10.1111/bjh.14640
TODO - daclatasvir;  dasabuvir;  deferiprone;  deferoxamine;  ledipasvir plus sofosbuvir;  ombitasvir plus paritaprevir plus ritonavir;  ribavirin;  simeprevir;  sofosbuvir;  antivirus agent;  BMS-790052;  imidazole derivative;  ribavirin;  simeprevir;  sofosbuvir, adult;  antiviral therapy;  Article;  blood transfusion;  chelation therapy;  chronic hepatitis C;  clinical article;  combination drug therapy;  drug efficacy;  drug safety;  drug tolerability;  female;  Hepatitis C virus genotype 1;  Hepatitis C virus genotype 2;  Hepatitis C virus genotype 3;  Hepatitis C virus genotype 4;  human;  liver cirrhosis;  male;  middle aged;  priority journal;  thalassemia major;  beta thalassemia;  chronic hepatitis C;  clinical trial;  complication;  genetics;  genotype;  Hepacivirus;  isolation and purification;  liver cirrhosis;  multicenter study;  severity of illness index;  virology, Adult;  Antiviral Agents;  beta-Thalassemia;  Drug Therapy, Combination;  Female;  Genotype;  Hepacivirus;  Hepatitis C, Chronic;  Humans;  Imidazoles;  Liver Cirrhosis;  Male;  Middle Aged;  Ribavirin;  Severity of Illness Index;  Simeprevir;  Sofosbuvir
TODO - Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for these patients. The aim of this study was to assess the safety and efficacy of DAAs in patients with β-TM and advanced liver disease due to CHC. Patients were recruited from eight liver units in Greece. The stage of liver disease was assessed using transient elastography and/or liver histology. Five regimens were used: sofosbuvir (SOF) + ribavirin (RBV); SOF + simeprevir ± RBV; SOF + daclatasvir ± RBV; ledipasvir/SOF ± RBV and ombitasvir/paritaprevir-ritonavir + dasabuvir ± RBV. Sixty-one patients (median age 43 years) were included. The majority of patients was previously treated for hepatitis C (75%) and had cirrhosis (79%). Viral genotype distribution was: G1a: n = 10 (16%); G1b: n = 22 (36%); G2: n = 2 (3%); G3: n = 14 (23%); G4: n = 13 (22%). The predominant chelation therapy was a combination of deferoxamine and deferiprone (35%). Overall sustained virological response rates were 90%. All treatment regimens were well tolerated and no major adverse events or drug-drug interactions were observed. Approximately half of the patients who received RBV (7/16, 44%) had increased needs for blood transfusion. Treatment of CHC with DAAs in patients with β-TM and advanced liver disease was highly effective and safe. © 2017 John Wiley & Sons Ltd
ER -